Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia

Journal of Medical Virology

Volumn 82, Issue 12, 2010, Pages 2013-2018

  Balode, Dace ^a,b   Westman, Maj ^a   Kolupajeva, Tatjana ^c   Rozentale, Baiba ^c   Albert, Jan ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Infectology Centre of Latvia   (Latvia)

Author keywords

Drug resistance mutations; HIV 1; Latvia; Primary resistance; Transmitted drug resistance

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LATVIA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; TRANSMITTED DRUG RESISTANCE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; LATVIA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78049365515     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21921     Document Type: Article

References (47)

1. Avi R, Huik K, Sadam M, Karki T, Krispin T, Ainsalu K, Paap P, Schmidt J, Nikitina N, Lutsar I. 2009. Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06_cpx in treatment-naive patients in Estonia. J Med Virol 81: 953-958.
2. Babic DZ, Zelnikar M, Seme K, Vandamme AM, Snoeck J, Tomazic J, Vidmar L, Karner P, Poljak M. 2006. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res 118: 156-163.
3. Balode D, Ferdats A, Dievberna I, Viksna L, Rozentale B, Kolupajeva T, Konicheva V, Leitner T. 2004. Rapid epidemic spread of HIV type 1 subtype A1 among intravenous drug users in Latvia and slower spread of subtype B among other risk groups. AIDS Res Hum Retroviruses 20: 245-249.
4. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. 2008a. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 13(Suppl 2): 1-13.
5. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. 2008b. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 13(Suppl 2): 25-36.
6. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. 2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4: e4724.
7. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D. 2009. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 23: 717-724.
8. de Joncheere K, Eramova I, Kehler J, Laukamm-Josten U, Rotberga S, Zakowicz A, Drew R. 2009. Evaluation of the access to HIV/AIDS treatment and care in Latvia. WHO.URL: .
9. Dusacka D, Guseva L, Kolupajeva T, Vrublevska J, Januskevica I, Vilde A, Storozenko J, Rozentale B. 2009. High prevalence of polymorphism in HIV1 variants ciculating in Latvia. April 28-30, 2009; Vilnius, Lithuania. p. PS2.2/1. URL: .
10. Ferdats A, Konicheva V, Dievberna I, Lilja E, Albert J. 1999. An HIV type 1 subtype A outbreak among injecting drug users in Latvia. AIDS Res Hum Retroviruses 15: 1487-1490.
11. Gifford RJ, Liu TF, Rhee SY, Kiuchi M, Hue S, Pillay D, Shafer RW. 2009. The calibrated population resistance tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 25: 1197-1198.
12. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT. 2008. The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr 49: 196-204.
13. Hall TA. 1999. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41: 95-98.
14. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 47: 266-285.
15. Infectology Center of Latvia. 2010a. HIV statistics. URL: .
16. Infectology Center of Latvia. 2010b. HIV therapy. URL: .
17. Jakobsen MR, Tolstrup M, Sogaard OS, Jorgensen LB, Gorry PR, Laursen A, Ostergaard L. 2010. Transmission of HIV-1 drug-resistant variants: Prevalence and effect on treatment outcome. Clin Infect Dis 50: 566-573.
18. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2009. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 17: 138-145.
19. Kolupajeva T, Aldins P, Guseva L, Dusacka D, Sondore V, Viksna L, Rozentale B. 2008. HIV drug resistance tendencies in Latvia. Cent Eur J Public Health 16: 138-140.
20. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ. 2003. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187: 683-686.
21. Lindström A, Albert J. 2003a. A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. J Virol Methods 107: 45-51.
22. Lindström A, Albert J. 2003b. Corrigendum to "A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1" [J. Virol. Methods 107 (2003) 45-51]. J Virol Methods 112: 165.
23. Lindström A, Ohlis A, Huigen M, Nijhuis M, Berglund T, Bratt G, Sandstrom E, Albert J. 2006. HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther 11: 1031-1039.
24. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385-394.
25. Liu TF, Shafer RW. 2006. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618.
26. Marks AJ, Pillay D, McLean AR. 2010. The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns. J Theor Biol 262: 1-13.
27. Murillo W, de Rivera IL, Parham L, Jovel E, Palou E, Karlsson AC, Albert J. 2010. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med 11: 95-103.
28. Myatt M, Bennett DE. 2008. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 13(Suppl 2): 37-48.
29. Pandit A, Mackay WG, Steel C, van Loon AM, Schuurman R. 2008. HIV-1 drug resistance genotyping quality assessment: Results of the ENVA7 Genotyping Proficiency Programme. J Clin Virol 43: 401-406.
30. Pandrea I, Descamps D, Collin G, Robertson DL, Damond F, Dimitrienco V, Gheorghita S, Pecec M, Simon F, Brun-Vezinet F, Apetrei C. 2001. HIV type 1 genetic diversity and genotypic drug susceptibility in the Republic of Moldova. AIDS Res Hum Retroviruses 17: 1297-1304.
31. Payne BA, Nsutebu EF, Hunter ER, Olarinde O, Collini P, Dunbar JA, Basta MS, Elston JW, Schmid ML, Thaker H, Chadwick DR. 2008. Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother 62: 464-468.
32. Poggensee G, Kucherer C, Werning J, Somogyi S, Bieniek B, Dupke S, Jessen H, Hamouda O. 2007. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 8: 511-519.
33. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, Shaefer M. 2007. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 8: 1-8.
34. Rumyantseva OA, Olkhovskiy IA, Malysheva MA, Ruzaeva LA, Vasiliev AV, Kazennova EV, Bobkova MR, Lukashov VV. 2009. Epidemiological networks and drug resistance of HIV type 1 in Krasnoyarsk region, Russia. AIDS Res Hum Retroviruses 25: 931-936.
35. Santoro MM, Ciccozzi M, Alteri C, Montieri S, Alexiev I, Dimova I, Ceccherini-Silberstein F, Beshkov D, Rezza G, Perno CF. 2008. Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria. AIDS Res Hum Retroviruses 24: 1133-1138.
36. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 41: 439-446.
37. Stanczak GP, Stanczak JJ, Firlag-Burkacka E, Wiercinska-Drapalo A, Leszczyszyn-Pynkad M, Jablonowska E, Malolepsza E, Horban A. 2007. Transmission of HIV-1 drug resistance among newly diagnosed patients in Poland. Przegl Epidemiol 61: 29-34.
38. Sukhanova AL, Bogoslovskaia EV, Kruglova AI, Bashkirova LI, Tsyganova GM, Shipulin GA, Kazennova EV, Alikina IuI, Zverev SI, Grishechkin AE, Pokrovskii VV, Bobkova MR, Bobkov AF. 2005. Protease and reverse transcriptase genetic polymorphism in HIV type 1 subtype A variants predominating in CIS countries. Mol Biol (Mosk) 39: 1063-1071.
39. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
40. The SPREAD Programme. 2008. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22: 625-635.
41. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, UK Register of HIV Seroconverters. 2007. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 21: 1035-1039.
42. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM. 2002. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 7: 123-129.
43. Vazquez de Parga E, Rakhmanova A, Perez-Alvarez L, Vinogradova A, Delgado E, Thomson MM, Casado G, Sierra M, Munoz M, Carmona R, Vega Y, Contreras G, Medrano L, Osmanov S, Najera R. 2005. Analysis of drug resistance-associated mutations in treatment-naive individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. J Med Virol 77: 337-344.
44. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kucherer C, Struck D, Schmit JC, Asjo B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA. 2009. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200: 1503-1508.
45. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, Jr., LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE. 2004. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189: 2174-2180.
46. Yerly S, von Wyl V, Ledergerber B, Boni J, Schupbach J, Burgisser P, Klimkait T, Rickenbach M, Kaiser L, Gunthard HF, Perrin L. 2007. Transmission of HIV-1 drug resistance in Switzerland: A 10-year molecular epidemiology survey. AIDS 21: 2223-2229.
47. Yerly S, Junier T, Gayet-Ageron A, Amari EB, von Wyl V, Gunthard HF, Hirschel B, Zdobnov E, Kaiser L. 2009. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 23: 1415-1423.